IDH1 and intrahepatic cholangiocarcinoma: Advanced iCC patients, after the evidence of progression on CSS and an adequate gene-typing revealing FGFR2 fusions/rearrangements or IDH1 mutations, may currently be included in dedicated clinical trials experimenting with targeted therapy [FGFR inhibitors or IDH inhibitors] and showing encouraging preliminary results [101,105,106].